Press Release
Global Gastric Cancer Treatment Market, by Treatment Type (Chemotherapy, Targeted Drugs Therapy, Radiation Therapy), By distribution channels (Hospitals, Clinics, long-term care centers, others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a healthy CAGR for the period between 2019 and 2027.
As per the report, growing prevalence of gastric adenocarcinoma and availability of new treatment options are the main factors driving growth of gastric cancer treatment market. According to American Cancer Society, approximately 27,510 new cases of gastric cancer are expected to be diagnosed in the U.S. in 2019. As per Globocan registry, globally 1,033,701 new cases of gastric cancer were diagnosed in 2018, and gastric cancer constitute 5.7% of all new cancer cases. Gastric cancer is usually diagnosed at an advanced stage with distant metastasis. Systemic chemotherapy is the first line of treatment in patients with metastatic gastric adenocarcinoma. 5-fluorouracil is the first chemotherapeutic agent of choice against metastatic gastric adenocarcinoma.
Recent advances in treatment such as immune checkpoint inhibitors have achieved significant increase in response rate to the treatment. However, cure of metastatic gastric adenocarcinoma is difficult with chemotherapy alone. Current treatment strategies are thus aimed at relieving symptoms and prolong the survival. Improving survival rates is another major factor pushing the gastric cancer treatment market. As per the results of latest clinical trials the median survival rate for metastatic gastric cancer is 6 to 13 months. Expanding aging population is another key factor driving growth of gastric cancer treatment market. As per American Cancer Society findings about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older.
